Foghorn Therapeutics Inc. FHTX R2K
Healthcare · Biotechnology · United States
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
READ MORE ›$4.28
+4.90% 1Y
Market & Price
Market Cap
$251.30M
Current Price
$4.28
High / Low (52W)
$6.68 / $3.53
Beta
2.97
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$-1.30
Price to Book
-3.29
P/S
8.90
EV/EBITDA
-1.41
Dividend Yield
-
Profitability & Returns
ROCE
-59.34%
ROE
-
ROA
-21.00%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-0.29
EPS (TTM)
$-1.17
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
2.85
Current Ratio
2.92
Debt
$41.99M
Total Assets
$198.10M
Current Assets
$163.24M
Working Capital
$103.50M
Ownership
Promoter Holding
17.94%
Chg in Prom Hold
-
FII / Inst Holding
76.49%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$109.66M
Total Revenue (TTM)
$28.22M
EBITDA
$-78.02M
Free Cash Flow
$-36.93M
Operating Cash Flow
$-87.40M
Shares Outstanding
58.71M
Gross Margin
-
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
17.14%
Profit 5Y
10.59%
Revenue (YoY)
-45.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 17.1% over 5 years.
- Profit CAGR of 10.6% over 5 years.
CONS
- Trading 35.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FHTX Foghorn Therapeutics Inc. R2K | 4.28 | - | $251.30M | - | -59.34% | - | 17.14% | 10.59% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 179.00K | 286.00K | 279.00K | 41.00K | 3.92M | 4.49M | 6.63M | 5.31M | 5.60M | 17.48M | 5.05M | 6.89M | - | - | 5.95M | 7.56M | 8.15M | 9.25M | 3.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.86M | 28.65M | 26.65M | 28.84M | 24.84M |
| Operating Income | -13.10M | -13.72M | -15.54M | -18.49M | -23.13M | -23.26M | -26.26M | -27.80M | -29.19M | -28.26M | -33.32M | -32.05M | -17.08M | -28.19M | -26.63M | - | - | -22.91M | -21.10M | -18.50M | -19.60M | -21.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.09M | -20.25M | -17.65M | -18.79M | -21.34M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.83M | -17.94M | -15.85M | -21.66M | -19.88M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - |
| Net Income | -13.09M | -13.95M | -15.72M | -18.37M | -22.99M | -23.11M | -26.08M | -26.91M | -27.31M | -25.77M | -30.49M | -29.49M | -14.35M | -25.02M | -22.98M | - | - | -18.83M | -17.94M | -15.85M | -21.66M | -19.88M |
| Diluted EPS | - | - | -2.90 | -3.12 | -0.62 | -0.63 | -0.71 | -0.65 | -0.66 | -0.62 | -0.73 | -0.70 | -0.34 | -0.59 | -0.45 | -0.31 | - | -0.30 | -0.28 | -0.25 | - | -0.29 |
| R&D Expense | 11.29M | 11.50M | 13.63M | 16.11M | 18.73M | 18.64M | 20.49M | 24.51M | 25.97M | 26.93M | 29.98M | 29.25M | 26.25M | 25.53M | 23.80M | 24.69M | - | 21.63M | 21.79M | 20.00M | - | 18.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 430.00K | - | 19.23M | 34.16M | 22.60M | 30.91M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 136.37M | 142.06M | 122.89M | 113.02M |
| Operating Income | -51.08M | -68.53M | - | -117.14M | -107.91M | -100.28M | -82.11M |
| EBITDA | - | - | - | -113.82M | -104.45M | -97.17M | -78.78M |
| Interest Expense | - | - | 1.91M | 0 | - | - | - |
| Pretax Income | - | - | - | -108.88M | -94.20M | -86.62M | -74.28M |
| Tax Provision | - | - | - | 0 | 4.23M | 0 | - |
| Net Income | -51.13M | -68.80M | - | -108.88M | -98.43M | -86.62M | -74.28M |
| Diluted EPS | - | -6.23 | -2.73 | -2.62 | -2.34 | -1.58 | - |
| R&D Expense | 44.36M | 57.72M | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
Compounded Sales Growth
| 5 Years: | 17.14% |
| 1 Year: | -45.10% |
Compounded Profit Growth
| 5 Years: | 10.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +4.90% |
| 6 Months: | -9.32% |
| 3 Months: | -24.65% |
| 1 Month: | -10.08% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.34M | 255.59M | - | 404.88M | 285.92M | 283.98M | 198.10M |
| Current Assets | - | - | - | - | 351.40M | 240.18M | 249.60M | 163.24M |
| Cash & Equivalents | - | 14.98M | 92.80M | - | 52.21M | 80.34M | 55.45M | 80.88M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 300.00M | 0 | - | - | - |
| Total Liabilities | - | 23.81M | 109.41M | - | 404.77M | 363.11M | 329.51M | 306.60M |
| Current Liabilities | - | 12.65M | 18.85M | - | 55.20M | 58.44M | 66.99M | 59.74M |
| Long Term Debt | - | 10.96M | 19.65M | - | - | - | - | - |
| Total Debt | - | - | - | - | 51.51M | 45.07M | 37.13M | 41.27M |
| Total Equity | -39.27M | -88.02M | 146.19M | - | 112.00K | -77.19M | -45.53M | -108.50M |
| Shares Outstanding | - | - | - | - | 41.80M | 42.28M | 55.59M | 56.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.34M | -31.29M | - | 193.61M | -118.11M | -100.41M | -86.10M |
| Investing Cash Flow | -964.00K | -108.91M | - | -244.32M | 144.45M | -29.90M | 112.04M |
| Financing Cash Flow | 23.97M | 217.47M | - | 1.76M | 1.78M | 105.43M | 1.02M |
| Capital Expenditure | -968.00K | -16.18M | - | -1.21M | -1.22M | -906.00K | -50.00K |
| Free Cash Flow | -47.30M | -47.47M | - | 192.40M | -119.33M | -101.31M | -86.15M |
| Net Change in Cash | - | - | - | -48.95M | 28.12M | -24.88M | 26.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | -15,937.4% | - | -609.2% | -315.9% | -443.7% | -265.6% |
| Net Margin % | - | -16,000.0% | - | -566.3% | -288.2% | -383.2% | -240.3% |
| ROE % | 58.1% | -47.1% | - | -97,216.1% | 127.5% | 190.3% | 68.5% |
| ROCE % | -527.2% | -28.9% | - | -33.5% | -47.4% | -46.2% | -59.3% |
Shareholding Pattern
Insiders
17.94%
Institutions
76.49%
Public Float
93.21%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Flagship Pioneering LLC | 21.59% | 12.67M | $54.25M |
| 2 | FMR, LLC | 10.30% | 6.05M | $25.88M |
| 3 | BVF Inc. | 9.95% | 5.84M | $25.00M |
| 4 | Deerfield Management Company, L.P | 7.48% | 4.39M | $18.81M |
| 5 | Raymond James Financial, Inc. | 4.43% | 2.60M | $11.14M |
| 6 | Blackrock Inc. | 4.03% | 2.36M | $10.12M |
| 7 | Euclidean Capital Llc | 2.68% | 1.57M | $6.74M |
| 8 | Vanguard Capital Management LLC | 2.55% | 1.50M | $6.40M |
| 9 | Geode Capital Management, LLC | 1.44% | 848.17K | $3.63M |
| 10 | Siren, L.L.C. | 1.23% | 720.72K | $3.08M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FHTX
No recent headlines available.